Ahn-Gook Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Ahn-Gook Pharmaceutical makes prescription medicines, including treatments for coughs and cardiovascular conditions, as well as health supplements such as an eye-health product called Tovicom, supplying patients and healthcare providers across South Korea.
It is listed on KOSDAQ, South Korea's small-cap and technology board. Alongside its branded products, the company operates a contract manufacturing business, producing medicines for other pharmaceutical companies from its factory in Hwaseong.
Summary is AI-generated and may contain errors · figures from DART filings
The company runs its own online distribution channel, 'Awonder', and is expanding into healthcare and beauty categories beyond its core pharmaceutical lines.
Ahn-Gook Pharmaceutical in five facts
What does Ahn-Gook Pharmaceutical do?
Ahn-Gook Pharmaceutical makes prescription medicines, including treatments for coughs and cardiovascular conditions, as well as health supplements such as an eye-health product called Tovicom, supplying patients and healthcare providers across South Korea.
Where is Ahn-Gook Pharmaceutical listed and in which sector?
Ahn-Gook Pharmaceutical (Korean name: 안국약품) trades under KRX code 001540 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Ahn-Gook Pharmaceutical?
Its market capitalisation was US$92.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Ahn-Gook Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Ahn-Gook Pharmaceutical reported revenue of US$231.6M, operating profit of US$7.4M and net income of US$5.5M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 13.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 21
- Material event reportOct 15
- Report on large shareholdings (5% rule) (standard)Sep 11
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Ahn-Gook Pharmaceutical reported consolidated results for FY2025: revenue of US$213M (+13.2% year on year), operating profit of US$6.82M (+46.6% year on year) and net income of US$5.24M (−53.8% year on year).
Earnings · Feb 25 - Cash/in-kind dividend decision
Ahn-Gook Pharmaceutical declared a cash dividend of US$0.44 per share.
Dividend · Feb 25